Top Page
China Health Group
(0673)
China Health Group (0673) vs. iShares MSCI Hong Kong ETF (EWH)
China Health Group Business Overview & Revenue Model
China Health Group Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 48.27M | 38.94M | 59.93M | 76.41M | 107.03M | 87.89M |
| Gross Profit | 8.52M | 9.23M | 13.64M | 27.19M | 28.69M | 25.99M |
| EBITDA | -36.03M | -63.71M | -37.42M | -33.04M | -4.38M | -1.47M |
| Net Income | -42.51M | -67.79M | -40.19M | -42.05M | -12.21M | -7.74M |
Balance Sheet | ||||||
| Total Assets | 187.16M | 147.35M | 192.32M | 221.19M | 225.96M | 217.82M |
| Cash, Cash Equivalents and Short-Term Investments | 2.41M | 1.05M | 4.01M | 11.48M | 8.54M | 4.59M |
| Total Debt | 5.54M | 6.50M | 5.66M | 6.04M | 18.47M | 5.36M |
| Total Liabilities | 135.74M | 147.25M | 132.56M | 127.23M | 140.82M | 117.83M |
| Stockholders Equity | 43.94M | -7.66M | 52.04M | 86.33M | 79.58M | 95.04M |
Cash Flow | ||||||
| Free Cash Flow | -3.67M | -8.35M | -7.03M | -9.59M | 31.00M | -10.90M |
| Operating Cash Flow | -3.05M | -6.76M | -6.40M | -8.22M | 31.80M | -9.06M |
| Investing Cash Flow | 190.00K | -1.58M | -301.00K | -5.40M | -35.29M | -1.84M |
| Financing Cash Flow | 1.46M | 8.79M | -1.24M | 27.66M | 12.96M | 2.63M |
China Health Group Technical Analysis
China Health Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$62.54B | 8.51 | 8.74% | 3.69% | -2.68% | -21.45% | |
71 Outperform | $65.17B | 7.24 | 7.53% | 2.69% | 2.77% | 39.24% | |
65 Neutral | HK$9.68B | 51.47 | 5.07% | 1.42% | 0.33% | -44.28% | |
52 Neutral | HK$910.61M | -6.13 | -305.54% | ― | -35.02% | -64.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
40 Underperform | HK$746.39M | -0.67 | -69.05% | ― | -43.86% | -217.25% |
China Health Group Corporate Events
China Health Group Limited, a company incorporated in Bermuda and operating in Hong Kong as CHG HS Limited, has announced the composition of its board of directors and the roles within its three board committees. The announcement details the executive, non-executive, and independent non-executive directors, as well as the members and chairpersons of the audit, nomination, and remuneration committees. This update provides stakeholders with clarity on the governance structure of the company, potentially impacting its strategic direction and operational oversight.
The most recent analyst rating on (HK:0673) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Health Group stock, see the HK:0673 Stock Forecast page.
China Health Group Limited has announced significant changes in its leadership structure, appointing Mr. Cao Xu as the new executive director and chairman of the board, effective October 31, 2025. Mr. Cao brings extensive experience in investments and the pharmaceutical industry, which is expected to enhance the company’s strategic direction and strengthen its market position. Additionally, Ms. Ying Rensi has been appointed as an executive director, further contributing to the company’s leadership team.
The most recent analyst rating on (HK:0673) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Health Group stock, see the HK:0673 Stock Forecast page.
China Health Group Limited has successfully completed the subscription of new shares and a rights issue, raising approximately HK$84.7 million in gross proceeds. The net proceeds of HK$80.9 million will be used to settle various financial obligations, including payables, loans, overdue salaries, and directors’ remuneration, as well as to provide working capital for daily operations.
The most recent analyst rating on (HK:0673) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Health Group stock, see the HK:0673 Stock Forecast page.
China Health Group Limited announced the results of its Rights Issue, which offered three Rights Shares for every ten shares held. The Rights Issue was undersubscribed by 18.9%, but all unsubscribed shares were successfully placed with independent placees, making the issue fully subscribed. The underwriting agreement conditions were fulfilled, and the Rights Issue became unconditional, ensuring no untaken rights shares remained.
The most recent analyst rating on (HK:0673) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Health Group stock, see the HK:0673 Stock Forecast page.
China Health Group Limited, operating in Hong Kong as CHG HS Limited and incorporated in Bermuda, held its Annual General Meeting (AGM) on September 26, 2025. At this meeting, all proposed resolutions were unanimously passed by the shareholders. These resolutions included the adoption of the company’s audited financial statements, the re-election of several directors, authorization for the board to appoint additional directors and fix their remuneration, the re-appointment of auditors, and granting mandates to the directors to issue and repurchase shares. The successful passing of these resolutions indicates strong shareholder support and positions the company for continued operational stability and strategic flexibility.
The most recent analyst rating on (HK:0673) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Health Group stock, see the HK:0673 Stock Forecast page.
China Health Group Limited has announced a revised timetable for its rights issue due to a tropical cyclone warning that affected the placement of unsubscribed rights shares. The placing of these shares, initially scheduled to conclude on 24 September 2025, has been extended to 25 September 2025. This adjustment impacts the overall proposal timeline, with the rights issue expected to become unconditional by 26 September 2025, and results announced by 3 October 2025. The changes are significant for stakeholders as they affect the timing and potential financial outcomes of the rights issue.
The most recent analyst rating on (HK:0673) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Health Group stock, see the HK:0673 Stock Forecast page.
China Health Group Limited announced the results of its Rights Issue, revealing that approximately 81.1% of the offered Rights Shares were subscribed, leaving 18.9% unsubscribed. To address the shortfall, the company has arranged for the remaining shares to be placed with new investors, with any net gain from this process to be distributed to shareholders who did not take action, highlighting the company’s efforts to manage shareholder interests and maintain financial stability.
The most recent analyst rating on (HK:0673) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Health Group stock, see the HK:0673 Stock Forecast page.
China Health Group Limited announced the results of a Special General Meeting (SGM) held on August 20, 2025, where all proposed resolutions were approved by independent shareholders. The meeting included the approval of Subscription Agreement A, which involves the issuance of 500,000,000 new shares to Subscriber A. Certain parties, including subscribers, underwriters, and placing agents, were required to abstain from voting due to their involvement in related agreements. The approval of these resolutions is expected to impact the company’s operations by potentially expanding its shareholder base and financial resources.
The most recent analyst rating on (HK:0673) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Health Group stock, see the HK:0673 Stock Forecast page.